Net loss widened significantly to $(10,043,831) in 2025 from $(1,780,240) in 2024, primarily due to a $9,451,890 impairment expense on digital currency. Revenue from telemedicine services decreased by 8% to $738,907 in 2025 from $802,704 in 2024, attributed to increased competition in the cannabis telemedicine industry. Operating expenses decreased by 14% to $1,019,906 in 2025, driven by reductions in professional fees, depreciation, wages, and advertising. Cash on hand decreased to $29,553 at December 31, 2025, from $34,934 in 2024. The company has an accumulated deficit of $84,389,964 as of December 31, 2025, which raises substantial doubt about its ability to continue as a going concern. A special distribution of Dogecoin Cash Units was declared to shareholders of record as of December 22, 2025, with the underlying tokens not withdrawable until January 7, 2027.